Hints and tips:
Related Special Reports
...Now based in Leverkusen — whose Bayer-owned football club could win the Bundesliga for the first time in its 120-year history — the executive is drawing on close to 30 years of experience in pharma and biotech...
...A former Roche manager who joined the German group last year, Anderson said he acknowledged the appeal of a “pure play structure” of pharma, crop science and over-the-counter consumer drugs....
...On Thursday, Bayer also announced the early departure of the head of its consumer health unit, Heiko Schipper, who will be replaced by Julio Triana, a senior manager in the group’s pharma division....
...Bayer paid a dividend of €2.40 for 2022. Analysts had expected Bayer to pay a dividend of €1.92 per share for 2023, a far more modest cut....
...Manns said asundexian was the most promising drug in Bayer’s pharma pipeline. “Without it, the pharma unit is left without sustainable growth.”...
...The new chief executive, who has been in the job since the summer and previously ran Roche’s pharma division, disagreed that Bayer’s pharma unit was too small to keep up with larger rivals....
...“The company needs money to invest in pharma, which is subscale and has a pipeline issue,” said Marco Taricco, a partner at Bayer shareholder Bluebell Capital Partners who this week renewed his calls for...
...AstraZeneca’s transformation is the sort of turnaround that others in the sector, such as Germany’s Bayer, need to replicate....
...Bayer is exploring a carve-out of its crop science division or its consumer health unit as new chief executive Bill Anderson is looking into radical ways to improve the agriculture and pharma conglomerate...
...Crop science is the largest part of the business and would work as a standalone. There is also a case for splitting off pharma, which would be worth about €33bn....
...Bayer: Shares in the German pharma company continue their slide to their lowest level in more than a decade after a key late-stage trial for a potential blockbuster drug failed to show efficacy on Monday...
...Germany’s Bayer and French giant Sanofi, which makes polio vaccines, have followed suit....
...But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change. Anderson wishes to boost pharma, for example, by removing centralised research budgeting....
...German pharma and agrochemicals group Bayer said it will take a €2.5bn writedown on glyphosate as prices — as well as demand — for the controversial weedkiller are falling....
...Some investors fear that the uncertainty over Roundup’s financial burden could limit Anderson’s room for manoeuvre with regard to a potential separation of Bayer’s crop science business and its pharma unit...
...Need to know: business Bayer shares plummeted as much as 18 per cent after the German pharma company reported failure of a late-stage trial for its asundexian blood-thinner....
...In one of his first meetings with Bayer managers, Anderson played a clip from the film....
...As people close to the company insist, a key argument made against selling Bayer’s agricultural business to Monsanto was that the remaining pharma division would then be so small that it could easily become...
...Bayer’s next chief executive has said he will consider all options to address the “unique challenges” of the pharma and chemicals conglomerate and that the break-up investors are pushing for is not a foregone...
...AstraZeneca said in February it had chosen to open a $360mn factory in Ireland, rather than in the UK, because of a “discouraging tax rate”, while German drugmaker Bayer said last year that it had cut staff...
...Bayer: Shares in the German chemicals and pharma company gained 2 per cent after reports it may spin off its CropScience unit....
...He added that Bayer was “deprioritising Europe to some degree” and focusing on the US and China, where its pharma division has already established a significant market presence....
...Net debt as a multiple of ebitda should fall to two times by 2024 from a multiple of almost three in 2021. Even better, Bayer’s pharma unit has more than doubled its peak sales targets to over €12bn....
...This week the WSJ has an interview with Bill Anderson, chief executive of Bayer, the pharma company, about his radical experiment with ditching traditional management structures (and a lot of managers) in...
...He defended his record at Bayer, saying he was “very proud” of his seven years in the top job as well as his 35 years in various other roles at the pharma and agrochemicals conglomerate....
International Edition